A randomized comparative study of methylcobalamin, methylcobalamin plus pregabalin and methylcobalamin plus duloxetine in patients of painful diabetic neuropathy.

Abstract

CONTEXT:Diabetic neuropathy affects 10.5%–32.2% of diabetic population posing clinical burden onto society.AIMS:We aimed to study the efficacy, safety, and tolerability of methylcobalamin, methylcobalamin plus pregabalin, and methylcobalamin plus duloxetine in patients of painful diabetic neuropathy.SETTINGS AND DESIGN:It is a prospective, randomized, open-label, interventional, and parallel-group study done in patients of painful diabetic neuropathy.MATERIALS AND METHODS:A total of 100 patients were recruited and randomized to three study groups A, B, and C on methylcobalamin, methylcobalamin and pregabalin, and methylcobalamin and duloxetine, respectively. Patients were assessed at day 0 and 4, 8, and 12 weeks. The tuning fork test, monofilament test, Thermal Sensitivity testing, and Visual Analog Scale (VAS) were used to analyze vibration, pressure, thermal sensitivity, and pain.STATISTICAL ANALYSIS USED:The results are expressed as mean ± standard deviation. Appropriate statistical methods were used to calculate P value (<0.05 – significant).RESULTS:The increase in number of patients with vibration perception is 11.6%, 37.9%, and 41.4%; pressure sensation is 7.6%, 37.9%, and 37.9%; and thermal sensitivity is 15.4%, 31.1%, and 37.9% in Groups A, B, and C, respectively. The decrease in VAS scores is 0.58 ± 0.14, 3.82 ± 0.05, and 4.17 ± 0.48 in Groups A, B, and C correspondingly. The adverse effects reported in Groups A, B, and C are 0%, 6.9%, and 10.3%, respectively.CONCLUSIONS:Group C is more efficacious when compared to Groups A and B while Group B is safer.